Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
复制标题

DOI:
10.1002/gcc.20673
复制
发表时间:
2009-08
期刊:
Genes, chromosomes & cancer
影响因子:
--
通讯作者:
Gastier-Foster JM
Gastier-Foster JM
中科院分区:
其他
文献类型:
--
作者:
Barr FG;Duan F;Smith LM;Gustafson D;Pitts M;Hammond S;Gastier-Foster JM

文献摘要

参考文献

被引文献

相似文献

腺泡状横纹肌肉瘤(ARMS)是一种与骨骼肌谱系相关的侵袭性儿科癌症,其特征是复发性染色体易位。在ARMS类别中,存在临床和遗传异质性,这与“原发性”遗传事件与“继发性”事件协作产生具有不同临床特征的子集的前提一致。先前的研究表明,基因组扩增在ARMS中频繁发生。在目前的研究中,我们使用寡核苷酸阵列定位两个常见的扩增子的2 p24和12 q13-q14染色体区域。基于拷贝数阵列数据,我们将2 p24和12 q13-q14扩增的最小共同区域分别亚定位到含有DDX 1和MYCN基因的0.83 Mb区域和含有27个基因的0.55 Mb区域。使用荧光原位杂交测定超过100例病例中2 p24和12 q13-q14区域的拷贝数,我们分别在13%和12%的病例中检测到这些扩增子。与融合状态的比较显示2 p24扩增优先发生在PAX 3-FOXO 1或PAX 7-FOXO 1阳性的病例中,而12 q13-q14扩增优先发生在PAX 3-FOXO 1阳性的病例中。表达研究表明MYCN通常在2 p24扩增的病例中过表达,而在12 q13-q14扩增的病例中多个基因过表达。最后,虽然2 p24扩增与临床结果没有显著相关性,但12 q13-q14扩增与无失败和总生存率显著更差相关,这与基因融合状态无关。
Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric cancer that is related to the skeletal muscle lineage and characterized by recurrent chromosomal translocations. Within the ARMS category, there is clinical and genetic heterogeneity, consistent with the premise that “primary” genetic events collaborate with “secondary” events to give rise to subsets with varying clinical features. Previous studies demonstrated that genomic amplification occurs frequently in ARMS. In the current study, we used oligonucleotide arrays to localize two common amplicons to the 2p24 and 12q13-q14 chromosomal regions. Based on the copy number array data, we sublocalized the minimum common regions of 2p24 and 12q13-q14 amplification to a 0.83 Mb region containing the DDX1 and MYCN genes, and a 0.55 Mb region containing 27 genes, respectively. Using fluorescent in situ hybridization assays to measure copy number of the 2p24 and 12q13-q14 regions in over 100 cases, we detected these amplicons in 13% and 12% of cases, respectively. Comparison with fusion status revealed that 2p24 amplification occurred preferentially in cases positive for PAX3-FOXO1 or PAX7-FOXO1 while 12q13-q14 amplification occurred preferentially in PAX3-FOXO1-positive cases. Expression studies demonstrated that MYCN was usually overexpressed in cases with 2p24 amplification while multiple genes were overexpressed in cases with 12q13-q14 amplification. Finally, although 2p24 amplification did not have a significant association with clinical outcome, 12q13-q14 amplification was associated with significantly worse failure-free and overall survival that was independent of gene fusion status.
DOI: 10.1002/gcc.10026
发表时间: 2002-03-01
影响因子: 3.7
作者:
Bridge, JA;Liu, J;Barr, FG
通讯作者: Barr, FG
DOI: 10.1002/cncr.21819
发表时间: 2006-05-15
期刊: CANCER
影响因子: 6.2
作者:
Houillier, C;Lejeune, J;Sanson, M
通讯作者: Sanson, M
DOI: 10.1158/0008-5472.can-05-4578
发表时间: 2006-07-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Davicioni, Elai;Finckenstein, Friedrich Graf;Anderson, Michael J.
通讯作者: Anderson, Michael J.
DOI: 10.1038/sj.bjc.6602661
发表时间: 2005-07-11
影响因子: 8.8
作者:
通讯作者: --
DOI: 10.2353/jmoldx.2006.050124
发表时间: 2006-05-01
影响因子: 4.1
作者:
Barr, FG;Smith, LM;Breitfeld, PP
通讯作者: Breitfeld, PP